Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17790872 | 0.89 | ACHE (0.44) | ACHENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL4975556 | 0.85 | ACHE (0.50) | ACHENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL12070289 | 0.85 | ACHE (0.50) | ACHENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL4445444 | 0.83 | NPC1 (0.52) | ACHENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL21359259 | 0.83 | ACHE (0.51) | ACHENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL31614616 | 0.82 | ACHE (0.55) | ACHENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL10580487 | 0.82 | ACHE (0.55) | ACHENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL16587914 | 0.82 | NPC1 (0.48) | ACHENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL16722735 | 0.82 | NPC1 (0.48) | ACHENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL19355183 | 0.82 | GAA (0.43) | ACHENPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10251845-B2 | Fatty acid cysteamine conjugates and their use as activators of autophagy | CATABASIS PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20170258741-A1 | FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY | CATABASIS PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-5158808-A | Method of coating with a water borne composition | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1992-10-27 | — | — | US | disclosed |
| US-5039759-A | Water borne high solids coating compositions | TECHNOLOGY CORPORATION UNITED CARBIDE CHEMICALS AND PLASTICS (US) | 1991-08-13 | — | — | US | disclosed |
| EP-0212380-B1 | AQUEOUS HIGH SOLIDS COATING COMPOSITIONS | UNION CARBIDE CORPORATION (US) | 1990-09-19 | — | — | EP | disclosed |
| EP-0233253-A1 | CARBAMATE COATING COMPOSITIONS | UNION CARBIDE CORPORATION (US) | 1987-08-26 | — | — | EP | disclosed |
| US-4677168-A | Water borne high solids coating compositions | UNION CARBIDE CORPORATION, | 1987-06-30 | — | — | US | disclosed |
| EP-0212380-A2 | Aqueous high solids coating compositions | UNION CARBIDE CORPORATION (US) | 1987-03-04 | — | — | EP | disclosed |
| EP-0211359-A1 | High solids coating compositions | UNION CARBIDE CORPORATION (US) | 1987-02-25 | — | — | EP | disclosed |
| WO-1987000851-A1 | CARBAMATE COATING COMPOSITIONS | UNION CARBIDE CORPORATION (US) | 1987-02-12 | — | — | WO | disclosed |
| EP-0196112-A2 | Aqueous high solids coating compositions | UNION CARBIDE CORPORATION (US) | 1986-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258741-A1 | FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY | NDUFAB1, ATG7, HADHA | ACHE 3596/4885NPC1 415/4885RAB9A 499/4885 |
| US-10251845-B2 | Fatty acid cysteamine conjugates and their use as activators of autophagy | NDUFAB1, ATG7, NLN | ACHE 3343/4885NPC1 475/4885RAB9A 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.